Ran Nussbaum bought $15M of LBRX
director at LB PHARMACEUTICALS INC. 1,000,000 shares at an average of $15.00, traded Sep 12, 2025, filed Sep 16, 2025.
Score components
- +15RoleDirector
- +25Trade size$15.0M at market
- +10Relative to holdingsHoldings up 243%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001609805-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 12, 2025 | CConversion Common Stockindirect: See footnote | +411,681 | - | - | 411,681 | Sep 16, 2025 |
| Sep 12, 2025 | POpen-market purchase Common Stockindirect: See footnote | +1,000,000 | $15.00 | $15M | 1,411,681 | Sep 16, 2025 |
| Sep 12, 2025 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -10,000,000 | - | - | 0 | Sep 16, 2025 |
Related signals
Other insiders at LB PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | LB PHARMACEUTICALS INC | Vida Ventures GP III, L.L.C. owner | $5.0M 333,333 shares | +61% | |
| 57Moderate | LB PHARMACEUTICALS INC | Deep Track Biotechnology Master Fund, Ltd. owner | $40M 2,666,666 shares | +389% | |
| 57Moderate | LB PHARMACEUTICALS INC | Pontifax Management 4 G.P. (2015) Ltd. owner | $15M 1,000,000 shares | +243% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.